Table 1.
Characteristics for ET patients grouped according to interval between CRT and surgery
| 5–6 weeks (N = 23) | 7–8 weeks (N = 84) | 9–10 weeks (N = 74) | 11–12 weeks (N = 31) | 13–14 weeks (N = 5) | p value | |
|---|---|---|---|---|---|---|
| Age, years | 0.639 | |||||
| Mean (range) | 63 (45–79) | 63 (34–85) | 63 (36–84) | 65 (39–84) | 68 (62–76) | |
| <45 | – | 5 (6.0) | 3 (4.1) | 1 (3.2) | – | |
| 45–59 | 8 (34.8) | 19 (22.6) | 24 (32.4) | 5 (16.1) | – | |
| 60–74 | 11 (47.8) | 45 (53.6) | 39 (52.7) | 18 (58.1) | 4 (80.0) | |
| >75 | 4 (17.4) | 15 (17.9) | 8 (10.8) | 7 (22.6) | 1 (20.0) | |
| Sex | 0.549 | |||||
| Male | 17 (73.9) | 54 (64.3) | 42 (56.8) | 17 (54.8) | 3 (60.0) | |
| Female | 6 (26.1) | 30 (35.7) | 32 (43.2) | 14 (45.2) | 2 (40.0) | |
| Distance to anus, cm (n = 189)a | 0.284 | |||||
| 0–5 | 6 (42.9) | 48 (64.0) | 44 (67.6) | 22 (73.3) | 3 (60.0) | |
| 6–10 | 7 (50.0) | 20 (26.7) | 10 (15.4) | 5 (16.7) | 2 (40.0) | |
| >10 | 1 (7.1) | 5 (6.7) | 5 (7.7) | 1 (3.3) | – | |
| Unknown | – | 2 (2.7) | 6 (9.2) | 2 (6.7) | – | |
| Histology | 1.000 | |||||
| AC | 21 (91.3) | 77 (91.7) | 68 (91.9) | 29 (93.5) | 5 (100.0) | |
| MC | 2 (8.7) | 6 (7.1) | 6 (8.1) | 2 (6.5) | – | |
| SRCC | – | 1 (1.2) | – | – | – | |
| cT stage | 0.927 | |||||
| cT1 | – | – | – | – | – | |
| cT2 | 3 (13.0) | 13 (15.5) | 13 (17.6) | 6 (19.4) | – | |
| cT3 | 20 (87.0) | 71 (84.5) | 61 (82.4) | 25 (80.6) | 5 (100.0) | |
| Surgical procedure | 0.393 | |||||
| LAR | 6 (26.1) | 30 (35.7) | 26 (35.1) | 10 (32.3) | 3 (60.0) | |
| APR | 16 (69.6) | 45 (53.6) | 40 (54.1) | 14 (45.2) | 1 (20.0) | |
| Hartmann | 1 (4.3) | 5 (6.0) | 3 (4.1) | 2 (6.5) | 1 (20.0) | |
| Other | – | 4 (4.8) | 5 (6.8) | 5 (16.1) | – | |
| ypT stage | 0.342 | |||||
| ypT0 | 8 (34.8) | 12 (14.3) | 18 (24.3) | 4 (12.9) | 2 (40.0) | |
| ypT1 | 2 (8.7) | 8 (9.5) | 6 (8.1) | 6 (19.4) | – | |
| ypT2 | 4 (17.4) | 29 (34.5) | 18 (24.3) | 11 (35.5) | – | |
| ypT3 | 9 (39.1) | 33 (39.3) | 28 (37.8) | 10 (32.3) | 3 (60.0) | |
| ypT4 | – | – | – | – | – | |
| ypTx | – | 2 (2.4) | 4 (5.4) | – | – | |
| ypN stage | 0.171 | |||||
| ypN0 | 19 (82.6) | 70 (83.3) | 55 (74.3) | 23 (74.2) | 3 (60.0) | |
| ypN1 | 3 (13.0) | 8 (9.5) | 6 (8.1) | 5 (16.1) | 2 (40.0) | |
| ypN2 | 1 (4.3) | 4 (4.8) | 4 (5.4) | – | – | |
| ypNx | – | 2 (2.4) | 9 (12.2) | 3 (9.7) | – | |
| Differentiation | 0.203 | |||||
| Well | – | – | – | 2 (6.5) | – | |
| Intermediate | 3 (13.0) | 22 (26.2) | 18 (24.3) | 6 (19.4) | 3 (60.0) | |
| Poor | – | 5 (6.0) | 3 (4.1) | 2 (6.5) | – | |
| Unknown | 20 (87.0) | 57 (67.9) | 53 (71.6) | 21 (67.7) | 2 (40.0) |
Data are expressed as n (%) unless otherwise specified
AC adenocarcinoma not otherwise specified, MC mucinous adenocarcinoma, SRCC signet ring cell adenocarcinoma, LAR low anterior resection, APR abdominoperineal resection, ET early tumor, CRT chemoradiation therapy
aData were only available from 2008 and beyond